<a href="https://laohu8.com/S/ARTV">Artiva Biotherapeutics</a> reports Q3 2025 results with $123 million cash and investments
Artiva Biotherapeutics Inc. reported cash, cash equivalents, and investments of $123.0 million as of September 30, 2025, expected to fund operations into the second quarter of 2027. Research and development expenses were $17.6 million for the three months ended September 30, 2025, up from $13.5 million for the same period in 2024. General and administrative expenses totaled $5.3 million, compared to $4.8 million for the prior year period. Other income, net, was $1.4 million, compared to $0.9 million for the same period in 2024. During the quarter, Artiva announced a CFO transition and highlighted ongoing clinical trials, with initial clinical response data in refractory rheumatoid arthritis expected in the first half of 2026 and plans for FDA discussions regarding potential pivotal trial design.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artiva Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9573859-en) on November 12, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。